1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

Study Flaws, Data Integrity Issues Clog China Review System As Applications Soar

Total Filings Processed Up 33%

 
• By Brian Yang

Facing a 40% increase in investigational new drug applications, regulatory reviewers in China are scrambling to turn down hundreds of filings plagued by major study design flaws, inconsistent samples and quality control failures.

China growth
CHINA NEW DRUG FILINGS SOAR BUT DATA AND STUDY ISSUES REMAIN • Source: Alamy

To find how prevalent problems are in regulatory filings to start clinical trials and for product approvals in China, one doesn’t have to read far within China’s annual report on new drug reviews, released on 21 June by the National Medical Products Administration (NMPA), to find out.

In 2020, the regulatory agency approved 20 innovative new products, including 14 drugs, four traditional Chinese medicines and two biologics....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

Non-Opioid Analgesics Guidance On Chronic Pain: One Trial Plus Confirmatory Evidence May Be Enough

 
• By Laura Helbling

Alternative therapies designed to avoid, eliminate, or reduce the use of opioids may be eligible for Breakthrough Therapy Designation or Priority Review, the US FDA draft guidance says.

‘We Are Not The Dark Side Of The Force’ – EU Regulator Urges ATMP Firms To Use Advice Services

 
• By Eliza Slawther

While drug regulators are “conservative” by nature, the European Medicines Agency wants to help companies rather than rip their dossiers “into little pieces,” a senior regulatory assessor says.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US FDA’s Tidmarsh Takes On Surrogate Endpoints, Maybe Old Business Partner, On LinkedIn

 
• By Sarah Karlin-Smith

CDER Director George Tidmarsh said in a now deleted social media post that his center will evaluate surrogate endpoints. Tidmarsh mentioned "notable failures," including a lupus drug, where he has past business connections to the sponsor's board chair.

More from Pathways & Standards

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 
• By Bridget Silverman

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US FDA’s Tidmarsh Takes On Surrogate Endpoints, Maybe Old Business Partner, On LinkedIn

 
• By Sarah Karlin-Smith

CDER Director George Tidmarsh said in a now deleted social media post that his center will evaluate surrogate endpoints. Tidmarsh mentioned "notable failures," including a lupus drug, where he has past business connections to the sponsor's board chair.